InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.048 -0.347 (-87.85%)+
Announcement
Release
22 Dec 2025 8:25AM
Price at Release
$0.395
Full Release
download
Summary
Immutep Limited announced a positive update on their IMP761 Phase I clinical trial. This first-in-class LAG-3 agonist antibody is being studied for its potential to treat autoimmune diseases by targeting the root cause of these conditions. The Phase I trial, which includes single-ascending dose levels, has shown encouraging safety and efficacy results, including a significant reduction in T cell activity without serious adverse effects. The trial is set to continue with further updates expected, and the early data supports the potential of IMP761 to effectively manage autoimmune diseases by selectively silencing overactive memory T cells. Immutep continues to lead in LAG-3 related immunotherapies, aiming to expand its therapeutic applications and partnerships.
Key Points
  • Positive update on IMP761 Phase I clinical trial
  • IMP761 is a first-in-class LAG-3 agonist for autoimmune diseases
  • Trial shows significant reduction in T cell activity
  • Favourable safety profile observed with no serious adverse events
  • Further updates expected as trial continues
  • Potential to selectively silence overactive memory T cells
  • Part of Immutep's leadership in LAG-3 immunotherapies
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.